Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."

Divesting its Rx generics business took a disproportionate amount of time considering Perrigo Company PLC’s been operating for more than 130 years and it’s been in the prescription drug space for around 15 years.

More from Deals

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.

VC Fund Spies Opportunity In ‘Overlooked’ Consumer Health Market

 
• By 

Venture capital fund backed by Germany's Schwabe has €100m to invest in consumer health startups operating in categories such as sleep and mental health.

Cooper Partners With MagnaPharm For Central and Eastern Europe Distribution

 
• By 

Cooper takes another step in its international expansion strategy through a partnership with Romania’s MagnaPharm for the distribution and commercialization of its self-care brand portfolio in Central and Eastern Europe (CEE).

Cooper Partners With Conaxess For Nordics Distribution

 
• By 

The Aurelius-owned distributor will create a new business unit especially for this purpose, headed up by business director Patrik Hene.

More from Business

People On The Move: Appointments At GSCF, Kenvue, Barentz

 
• By 

A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.

Galenica OTC Goes From Strength To Strength At Home And Abroad

 
• By 

Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.